Erratum: Computational prediction of the cross-reactive neutralizing epitope corresponding to monoclonal antibody b12 specific for HIV-1 gp120 (Faseb Journal DOI:10.1096/fj.05-5509rev);Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120

FASEB Journal

Volumn 20, Issue 11, 2006, Pages 1762-1774

  Bublil, Erez M ^a   Yeger Azuz, Sharon ^a   Gershoni, Jonathan M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Combinatorial phage display peptide library; Epitope mapping; Mapitope algorithm; Vaccine design

Indexed keywords

CYSTEINE; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY B17B; MONOCLONAL ANTIBODY B6; MONOCLONAL ANTIBODY M14; CD4 ANTIGEN; DNA; PRIMER DNA;

ANTIBODY SPECIFICITY; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; CROSS REACTION; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MATHEMATICAL ANALYSIS; MUTAGENESIS; PANCREAS ISLET BETA CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; ALGORITHM; ANTIBODY COMBINING SITE; BIOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METHODOLOGY; SITE DIRECTED MUTAGENESIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; BINDING SITES, ANTIBODY; COMPUTATIONAL BIOLOGY; CROSS REACTIONS; DNA; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HIV ENVELOPE PROTEIN GP120; HUMANS; MUTAGENESIS, SITE-DIRECTED;

EID: 33748661250     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-5509rev     Document Type: Erratum

References (58)

1. Barquet, N., and Domingo, P. (1997) Smallpox: the triumph over the most terrible of the ministers of death. Ann. Intern. Med. 127, 635-642
2. Andre, F. E. (2003) Vaccinology: past achievements, present roadblocks and future promises. Vaccine 21, 593-595
3. Meissner, H. C., Strebel, P. M., and Orenstein, W. A. (2004) Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 114, 1065-1069
4. Vidor, E., Dumas, R., Porteret, V., Bailleux, F., and Veitch, K. (2004) Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur. J. Clin. Microbiol. Infect. Dis. 23, 300-309
5. Rustgi, V. K., Schleupner, C. J., and Krause, D. S. (1995) Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults. Vaccine 13, 1665-1668
6. Ruf, B. R., Colberg, K., Frick, M., and Preusche, A. (2004) Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 32, 191-198
7. Donnelly, J. J., Wahren, B., and Liu, M. A. (2005) DNA vaccines: progress and challenges. J. Immunol. 175, 633-639
8. Ruprecht, R. M., Ferrantelli, F., Kitabwalla, M., Xu, W., and McClure, H. M. (2003) Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine 21, 3370-3373
9. Mascola, J. R., Louder, M. K., VanCott, T. C., Sapan, C. V., Lambert, J. S., Muenz, L. R., Bunow, B., Birx, D. L., and Robb, M. L. (1997) Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71, 7198-7206
10. Zhang, Y. J., Fracasso, C., Fiore, J. R., Bjorndal, A., Angarano, G., Gringeri, A., and Fenyo, E. M. (1997) Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J. Infect. Dis. 176, 1180-1187
11. Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W., Sawyer, L. S., Hendry, R. M., Dunlop, N., Nara, P. L., et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027
12. Enshell-Seijffers, D., Denisov, D., Groisman, B., Smelyanski, L., Meyuhas, R., Gross, G., Denisova, G., and Gershoni, J. M. (2003) The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J. Mol. Biol. 334, 87-101
13. Berthet-Colominas, C., Monaco, S., Novelli, A., Sibai, G., Mallet, F., and Cusack, S. (1999) Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. EMBO J. 18, 1124-1136
14. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., and Hendrickson, W. A. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659
15. Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., Jr., and Leahy, D. J. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756-760
16. Villard, S., Lacroix-Desmazes, S., Kieber-Emmons, T., Piquer, D., Grailly, S., Benhida, A., Kaveri, S. V., Saint-Remy, J. M., and Granier, C. (2003) Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood 102, 949-952
17. Burton, D. R., Barbas, C. F., 3rd, Persson, M. A., Koenig, S., Chanock, R. M., and Lerner, R. A. (1991) A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. U. S. A. 88, 10134-10137
18. Pantophlet, R., Saphire, E. O., Poignard, P., Parren, P. W., Wilson, I. A., and Burton, D. R. (2003) Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77, 642-658
19. Enshell-Seijffers, D., and Gershoni, J. M. (2002) Phage display selection and analysis of Ab-binding epitopes. In Current Protocols in Immunology (Coico, R., ed) Vol. 2, pp. 9.8.1-9.8.27, John Wiley and Sons, New York
20. Enshell-Seijffers, D., Smelyanski, L., and Gershoni, J. M. (2001) The rational design of a 'type 88' genetically stable peptide display vector in the filamentous bacteriophage fd. Nucleic Acids Res. 29, E50-0
21. Gershoni, J. M., Denisova, G., Raviv, D., Smorodinsky, N. I., and Buyaner, D. (1993) HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. FASEB J. 7, 1185-1187
22. Bonnycastle, L. L., Mehroke, J. S., Rashed, M., Gong, X., and Scott, J. K. (1996) Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. J. Mol. Biol. 258, 747-762
23. Boots, L. J., McKenna, P. M., Arnold, B. A., Keller, P. M., Gorny, M. K., Zolla-Pazner, S., Robinson, J. E., and Conley, A. J. (1997) Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. AIDS Res. Hum. Retroviruses 13, 1549-1559
24. Zwick, M. B., Bonnycastle, L. L., Menendez, A., Irving, M. B., Barbas, C. F., 3rd, Parren, P. W., Burton, D. R., and Scott, J. K. (2001) Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J. Virol. 75, 6692-6699
25. Stern, B., Denisova, G., Buyaner, D., Raviv, D., and Gershoni, J. M. (1997) Helical epitopes determined by low-stringency antibody screening of a combinatorial peptide library. FASEB J. 11, 147-153
26. Roben, P., Moore, J. P., Thali, M., Sodroski, J., Barbas, C. F., 3rd, and Burton, D. R. (1994) Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68, 4821-4828
27. Saphire, E. O., Parren, P. W., Pantophlet, R., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R., and Wilson, I. A. (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293, 1155-1159
28. Barbas, C. F., 3rd, Bjorling, E., Chiodi, F., Dunlop, N., Cababa, D., Jones, T. M., Zebedee, S. L., Persson, M. A., Nara, P. L., Norrby, E., et al. (1992) Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 89, 9339-9343
29. Moore, J. P., and Sodroski, J. (1996) Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70, 1863-1872
30. (2003) VaxGen vaccine trial fails the test but may offer insights. AIDS Alert 1. 41, 43-45
31. James, J. S. (2003) First AIDS vaccine tested did not protect, but gives scientific leads. AIDS Treat News 6
32. Zolla-Pazner, S. (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4, 199-210
33. UNAIDS\WHO (2005) AIDS Epidemic Update. In http://www.unaids.org/ DocOrder/OrderForm.aspx
34. Burton, D. R. (2002) Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706-713
35. Douek, D. C., Kwong, P. D., and Nabel, G. J. (2006) The rational design of an AIDS vaccine. Cell 124, 677-681
36. Lehner, T. (2003) Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine 21 Suppl. 2, S68-S76
37. Mascola, J. R. (2003) Defining the protective antibody response for HIV-1. Curr. Mol. Med. 3, 209-216
38. Lehner, T., and Anton, P. A. (2002) Mucosal immunity and vaccination against HIV. Aids 16 Suppl. 4, S125-S132
39. Burton, D. R. (1997) A vaccine for HIV type 1: the antibody perspective. Proc. Natl. Acad. Sci. U. S. A. 94, 10018-10023
40. Burton, D. R., Stanfield, R. L., and Wilson, I. A. (2005) Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U. S. A. 102, 14943-14948
41. Pantophlet, R., and Burton, D. R. (2006) GP120: Target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. Epub ahead of print.
42. Sette, A., and Fikes, J. (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 15, 461-470
43. Raveche, E. S., Schutzer, S. E., Fernandes, H., Bateman, H., McCarthy, B. A., Nickell, S. P., and Cunningham, M. W. (2005) Evidence of Borrelia autoimmunity-induced component of Lyme carditis and arthritis. J. Clin. Microbiol. 43, 850-856
44. Alaedini, A., and Latov, N. (2005) Antibodies against OspA epitopes of Borrelia burgdorferi cross-react with neural tissue. J. Neuroimmunol. 159, 192-195
45. Bolz, D. D., and Weis, J. J. (2004) Molecular mimicry to Borrelia burgdorferi: pathway to autoimmunity? Autoimmunity 37, 387-392
46. Gross, D. M., Forsthuber, T., Tary-Lehmann, M., Etling, C., Ito, K., Nagy, Z. A., Field, J. A., Steere, A. C., and Huber, B. T. (1998) Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281, 703-706
47. Willett, T. A., Meyer, A. L., Brown, E. L., and Huber, B. T. (2004) An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc. Natl. Acad. Sci. U. S. A. 101, 1303-1308
48. Gorny, M. K., Conley, A. J., Karwowska, S., Buchbinder, A., Xu, J. Y., Emini, E. A., Koenig, S., and Zolla-Pazner, S. (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66, 7538-7542
49. Kwong, P. D. (2004) The 447-52D antibody: hitting HIV-1 where its armor is thickest. Structure 12, 173-174
50. Conley, A. J., Gorny, M. K., Kessler, J. A., 2nd, Boots, L. J., Ossorio-Castro, M., Koenig, S., Lineberger, D. W., Emini, E. A., Williams, C., and Zolla-Pazner, S. (1994) Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68, 6994-7000
51. Keller, P. M., Arnold, B. A., Shaw, A. R., Tolman, R. L., Van Middlesworth, F., Bondy, S., Rusiecki, V. K., Koenig, S., Zolla-Pazner, S., Conard, P., et al. (1993) Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology 193, 709-716
52. Steward, M. W., Stanley, C. M., and Obeid, O. E. (1995) A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response. J. Virol. 69, 7668-7673
53. Khurana, S., Kennedy, M., King, L. R., and Golding, H. (2005) Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity. J. Virol. 79, 6791-6800
54. Wu, L., LaRosa, G., Kassam, N., Gordon, C. J., Heath, H., Ruffing, N., Chen, H., Humblias, J., Samson, M., Parmentier, M., Moore, J. P., and Mackay, C. R. (1997) Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186, 1373-1381
55. Morris, G. M., Goodsell, R. S. Halliday, R. H., Hart, W. E., Belew, R. K., and Olson, A. J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comp. Chem. 19, 1639-1662
56. Tarnovitski, N., Matthews, L. J., Sui, J., Gershoni, J. M., and Marasco, W. A. (2006) Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. J. Mol. Biol. 359, 190-201
57. Zhang, M. Y., Xiao, X., Sidorov, I. A., Choudhry, V., Cham, F., Zhang, P. F., Bouma, P., Zwick, M., Choudhary, A., Montefiori, D. C., and Dimitrov, D. S., et al. (2004) Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J. Virol. 78, 9233-9242
58. Glaser, F., Pupko, T., Paz, I., Bell, R. E., Bechor-Shental, D., Martz, E., and Ben-Tal, N. (2003) ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics 19, 163-164